Why Are Pediatric Medicines Still in Short Supply? The Hidden Challenges Behind Global Pediatric Healthcare

Why Are Pediatric Medicines Still in Short Supply? The Hidden Challenges Behind Global Pediatric Healthcare

From reducing adult dosages for children to the lack of pediatric-specific formulations; from insufficient pediatric clinical data to limited access to medicines for children with rare diseases, pediatric medication challenges are not limited to one country alone, but represent a shared issue across global healthcare systems.

The problem is particularly evident in infants and young children, pediatric oncology, neurological disorders, and rare diseases, where access to suitable pediatric medicines remains especially limited.

Global pharmaceutical distributor DengYueMed explores the current shortage of pediatric medicines, the barriers in pediatric drug development, global supply challenges, and the future direction of pediatric healthcare systems worldwide.

The Shortage of Pediatric Medicines Has Become a Long-Term Global Reality

Compared with the adult pharmaceutical market, the global pediatric medicine system has developed at a much slower pace.

In many countries, the number of pediatric-specific medicines remains far lower than that of adult medicines.

Although many drugs are already widely used in adults, they still lack sufficient pediatric indication data, and some pediatric treatments continue to rely on experience-based dosage adjustments.

In reality, many families still:

• Reduce adult medicine dosages for children
• Split or crush tablets manually
• Estimate doses based on age
• Depend on non-pediatric formulations

Meanwhile, pediatricians and healthcare providers frequently face:

• Lack of pediatric indications
• Insufficient low-dose formulations
• Limited child-friendly dosage forms
• High rates of off-label drug use

During respiratory disease seasons, the demand for pediatric fever reducers, antiviral drugs, and anti-infective medications often rises significantly, further exposing the insufficient supply of pediatric medicines.

At the same time, the risks associated with inappropriate medication use in children are becoming increasingly apparent.

Challenges Are Even Greater in Pediatric Oncology and Rare Diseases

Among all pediatric medication challenges, pediatric oncology and rare diseases remain the most complex areas.

Examples include:

• Pediatric leukemia
• Neuroblastoma
• SMA
• DMD
• Pediatric epilepsy

These diseases often require long-term, highly individualized, and precision-based treatment strategies.

However, in reality, many innovative drugs are initially approved only for adults, while pediatric indications often take much longer to obtain approval.

This means that even if certain drugs are already widely available for adult patients, children may still be unable to access the same treatments in time.

At the same time, the limited number of pediatric rare disease patients also reduces commercial incentives for pharmaceutical companies.

For many families, medicines represent not only treatment opportunities, but also long-term financial pressure.

Why Has Pediatric Drug Development Lagged Behind for So Long?

The core issue behind pediatric medicine shortages is not simply insufficient supply, but rather structural challenges that have existed within the global pharmaceutical development system for decades.

Children Are Not Small Adults

Children differ significantly from adults in drug absorption, distribution, metabolism, and excretion.

There are also major differences among pediatric age groups:

• Newborns
• Infants
• School-age children
• Adolescents

Their pharmacokinetics and dosage requirements vary substantially.

As a result, simply reducing adult dosages cannot fully replace pediatric-specific medicines.

At the same time, children require more specialized dosage forms.

Young children often have difficulty swallowing standard tablets and capsules, making them more suitable for:

• Oral liquids
• Drops
• Suspensions
• Granules
• Orally disintegrating tablets

However, many drugs on the market are still primarily designed in adult formulations.

Pediatric Formulation Development Is More Complex

Compared with adult medicines, pediatric drugs require more precise dosage design and age-appropriate formulations.

Pediatric formulations usually demand:

• Smaller dosage strengths
• Higher safety standards
• Better taste stability
• Easier administration for children

For example, oral liquids, suspensions, and small-dose granules often involve more complicated development and manufacturing processes.

For pharmaceutical companies, this translates into higher development and production costs.

As a result, many drugs continue to prioritize adult formulations before pediatric versions are developed.

Pediatric Clinical Trials Are More Difficult

One of the biggest barriers to pediatric drug development is that pediatric clinical research is significantly more complicated than adult trials.

Because minors are involved, pediatric clinical studies require stricter ethical review processes.

At the same time:

• Recruiting participants is more difficult
• Age stratification is more complex
• Long-term safety requirements are stricter
• Follow-up periods are longer

All of these factors increase development complexity.

Even drugs that are already widely used in adults may still lack sufficient pediatric clinical data.

As a result, many pediatric treatments continue to rely heavily on clinical experience.

Limited Commercial Returns Reduce Industry Incentives

From a market perspective, pediatric medicines are generally not considered highly profitable products.

Compared with adult chronic disease therapies, pediatric drugs often involve:

• Smaller patient populations
• Shorter treatment durations
• Higher formulation development costs
• Greater clinical trial investment

As a result, some companies prioritize adult drug markets first.

This issue becomes even more significant in pediatric rare diseases, where development costs are high while patient populations remain limited.

Global Healthcare Inequality Further Expands the Problem

Pediatric drug accessibility issues are even more severe in low-income countries and remote regions.

Some areas still face:

• Shortages of essential pediatric medicines
• Limited vaccine coverage
• Insufficient cold-chain transportation systems
• Inadequate medicine reserves in primary healthcare settings

Even in countries with relatively advanced healthcare systems, pediatric specialty medicines are often concentrated in major medical centers.

Smaller cities and primary healthcare institutions still face major barriers in accessing pediatric medicines.

How Is the World Improving Pediatric Medication Systems?

In recent years, many countries and international organizations have increased support for pediatric drug development.

Examples include:

• Promoting pediatric indication research
• Establishing pediatric priority review programs
• Providing R&D subsidies and tax incentives
• Encouraging pediatric-specific formulation development
• Extending market exclusivity for certain pediatric drugs

Regulatory agencies are increasingly emphasizing that children should no longer be overlooked in new drug development.

Some innovative medicines now begin pediatric research programs shortly after adult approval.

At the same time, global pediatric medicine supply systems are gradually improving.

More international healthcare institutions, pharmaceutical supply platforms, and cross-border medical service providers are paying closer attention to pediatric drug accessibility.

For some children with rare diseases, international pharmaceutical collaboration and cross-border medical resources are becoming important pathways to accessing treatment opportunities.

AI and New Technologies Are Transforming Pediatric Drug Development

In recent years, AI and digital technologies have gradually entered the field of pediatric drug development.

Compared with traditional development models, new technologies can help researchers:

• Predict pediatric pharmacokinetics
• Simulate dosage requirements across age groups
• Optimize clinical trial design
• Improve safety evaluation efficiency
• Reduce development costs

At the same time:

• Real-world studies
• Digital clinical trials
• Pediatric drug modeling technologies
• Global data-sharing platforms

are continuing to evolve.

These technologies may help address the long-standing shortage of pediatric data and improve the development efficiency of innovative pediatric therapies.

Conclusion

Pediatric medication challenges are not simply about drug shortages, but rather reflect long-term structural issues within global pediatric healthcare systems, pharmaceutical R&D systems, and supply chains.

In recent years, with the advancement of AI technologies, real-world research, international pharmaceutical collaboration networks, and pediatric drug incentive policies, global pediatric drug development has gradually improved. However, a significant gap still remains between actual clinical demand and available treatment options.

DengYueMed believes that the future of pediatric healthcare requires not only more innovative therapies, but also stronger global supply chains, better pediatric formulation design, and more stable international drug accessibility systems.

Only when children can truly access safe, precise, and age-appropriate treatments can the gaps within global pediatric healthcare systems gradually be reduced.